|
🐜
|
Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine.
26 auth.
R. Itzykson,
S. Thépot,
B. Quesnel,
F. Dreyfus,
O. Beyne-Rauzy,
P. Turlure,
N. Vey,
C. Récher,
C. Dartigeas,
L. Legros,
J. Delaunay,
C. Salanoubat,
Sorin Visanica,
A. Stamatoullas,
F. Isnard,
...
A. Marfaing‐Koka,
S. de Botton,
Y. Chelghoum,
A. Taksin,
I. Plantier,
S. Amé,
S. Boehrer,
C. Gardin,
C. L. Beach,
L. Adès,
P. Fenaux
|
8 |
2011 |
8
🐜
|
|
🐜
|
The revised IPSS is a powerful tool to evaluate the outcome of MDS patients treated with azacitidine: the GFM experience.
17 auth.
Mathilde Lamarque,
S. Raynaud,
R. Itzykson,
S. Thépot,
B. Quesnel,
F. Dreyfus,
O. Rauzy,
P. Turlure,
N. Vey,
C. Récher,
...
C. Dartigeas,
L. Legros,
J. Delaunay,
Sorin Visanica,
A. Stamatoullas,
P. Fenaux,
L. Adès
|
5 |
2012 |
5
🐜
|
|
🐜
|
PICALM-MLLT10 acute myeloid leukemia: a French cohort of 18 patients.
19 auth.
C. Borel,
N. Dastugue,
V. Cancès-Lauwers,
M. Mozziconacci,
T. Prebet,
N. Vey,
A. Pigneux,
E. Lippert,
Sorin Visanica,
F. Legrand,
...
J. Rault,
S. Taviaux,
C. Bastard,
F. Mugneret,
Marie Agnes Collonges Rames,
N. Gachard,
P. Talmant,
É. Delabesse,
C. Récher
|
5 |
2012 |
5
🐜
|
|
🐜
|
Treatment with lenalidomide does not appear to increase the risk of progression in lower risk myelodysplastic syndromes with 5q deletion. A comparative analysis by the Groupe Francophone des Myelodysplasies
20 auth.
L. Adès,
Fabien Le Bras,
M. Sébert,
C. Kelaidi,
T. Lamy,
F. Dreyfus,
V. Eclache,
J. Delaunay,
D. Bouscary,
Sorin Visanica,
...
P. Turlure,
Agnès Guerci Bresler,
M. Cabrol,
A. Banos,
M. Blanc,
N. Vey,
A. Delmer,
E. Wattel,
S. Chevret,
P. Fenaux
|
5 |
2012 |
5
🐜
|
|
🐜
|
Treatment by Lenalidomide in lower risk myelodysplastic syndrome with 5q deletion--the GFM experience.
20 auth.
Fabien Le Bras,
M. Sébert,
C. Kelaidi,
T. Lamy,
F. Dreyfus,
J. Delaunay,
A. Banos,
M. Blanc,
N. Vey,
Aline Schmidt,
...
Sorin Visanica,
V. Eclache,
P. Turlure,
O. Beyne-Rauzy,
A. Guerci,
A. Delmer,
S. de Botton,
D. Réa,
P. Fenaux,
L. Adès
|
5 |
2011 |
5
🐜
|
|
🐜
|
Personalized daily doses of imatinib by therapeutic drug monitoring increase the rates of molecular responses in patients with Chronic Myeloid Leukemia - Final results of the randomized Optim imatinib study: Co-028
21 auth.
P. Rousselot,
H. Johnson-Ansah,
F. Huguet,
L. Legros,
M. Escoffre-barbe,
M. Gardembas,
P. Cony-Makhoul,
V. Coiteux,
L. Sutton,
Wajed Abarah,
...
Camille Pouaty,
J. Pignon,
B. Choufi,
Sorin Visanica,
B. Deau,
S. Bouchet,
F. Guilhot,
F. Mahon,
Laure Morisset,
J. Cayuela,
B. Manéglier
|
4 |
2015 |
4
🐜
|
|
🐜
|
Azacitidine improves outcome in higher‐risk MDS patients with chromosome 7 abnormalities: a retrospective comparison of GESMD and GFM registries
31 auth.
M. Díez-Campelo,
J. Lorenzo,
R. Itzykson,
S. Rojas,
C. Berthon,
E. Luño,
O. Beyne-Rauzy,
J. Pérez-Oteyza,
N. Vey,
J. Bargay,
Sophie Park,
T. Cedena,
D. Bordessoule,
J. Muñoz,
E. Gyan,
...
E. Such,
Sorin Visanica,
F. López-Cadenas,
S. de Botton,
J. Hernández-Rivas,
S. Amé,
A. Stamatoullas,
J. Delaunay,
C. Salanoubat,
F. Isnard,
R. Guièze,
Joan Pérez Guallar,
L. Badiella,
G. Sanz,
C. Cañizo,
P. Fenaux
|
3 |
2018 |
3
🐜
|
|
🐜
|
Imatinib Optimized Therapy Improves Major Molecular Response Rates in Patients with Chronic Myeloid Leukemia
26 auth.
H. Johnson-Ansah,
B. Manéglier,
F. Huguet,
L. Legros,
M. Escoffre-barbe,
M. Gardembas,
P. Cony-Makhoul,
V. Coiteux,
L. Sutton,
Wajed Abarah,
Camille Pouaty,
J. Pignon,
B. Choufi,
Sorin Visanica,
B. Deau,
...
Laure Morisset,
E. Cayssials,
M. Molimard,
S. Bouchet,
F. Mahon,
F. Nicolini,
P. Aegerter,
J. Cayuela,
M. Delord,
H. Bruzzoni-Giovanelli,
P. Rousselot
|
3 |
2022 |
3
🐜
|
|
🐜
|
Revised-IPSS (IPSS-R) Is a Powerful Tool to Evaluate the Outcome of MDS Patient Treated with Azacitidine (AZA): The Groupe Francophone Des Myelodysplasies (GFM) Experience
17 auth.
L. Adès,
Mathilde Lamarque,
S. Raynaud,
R. Itzykson,
S. Thépot,
B. Quesnel,
F. Dreyfus,
O. Rauzy,
P. Turlure,
N. Vey,
...
C. Récher,
C. Dartigeas,
L. Legros,
J. Delaunay,
Sorin Visanica,
A. Stamatoullas,
P. Fenaux
|
3 |
2012 |
3
🐜
|
